

Minutes of the 273rd (overall) and 141st meeting of the Authority under DPCO, 2013 held on 23.12.2025 at 12:00 PM.

The 273rd meeting of the Authority (overall), which is the 141st meeting under the DPCO, 2013 was held on 23rd December, 2025 at 12:00 PM under the Chairmanship of Shri P. Krishnamurthy, Chairman, NPPA. The following Authority members were present during the meeting:

- (i) Ms. Sai Ahlladini Panda, Member Secretary, NPPA
- (ii) Shri Manmohan Sachdeva, Additional Chief Adviser Cost (ACAC) & Shri Vijay Kumar, Adviser (Cost), O/o Chief Adviser (Cost), Department of Expenditure.
- (iii) Dr. Rose Mary K. Abraham, Economic Advisor, Department of Economic Affairs

The following officers of NPPA attended the meeting and assisted the Authority in its deliberations:

- (i) Shri Sanjay Kumar, Advisor (Cost)
- (ii) Ms. Rashmi Tahiliani, Director (Pricing)
- (iii) Shri Kumar Aman Bharti, Director (M&E)
- (iv) Shri Mahaveer Saini, Deputy Director (Pricing)
- (v) Ms. Yuvika Panwar, Assistant Director (Pricing)
- (vi) Shri Bhiva Ram Yadav, Assistant Director (Pricing)
- (vii) Shri Mayur Panwar, Assistant Director (Pricing)

1. Agenda item no. 1 - Confirmation of the Minutes of the 140th Meeting and Record Note of Discussion held on 27.11.2025.

1.1 The Authority confirmed the minutes of the meeting and Record Note of Discussion without any change.

2. Agenda item no. 2 - Action Taken Report (ATR) on decisions taken by NPPA in its 140th Meeting held on 27.11.2025.

2.1 Noted.

3. Agenda item no. 3 - Status of new drug application.

3.1 Noted.



4. Agenda item no. 4 – New Drug application for price fixation under Paragraph 5 and 15 of DPCO, 2013.

4.1 The Authority deliberated on 37 (Thirty-Seven) cases of retail price fixation of new drugs as presented in Agenda no. 4(1) to 4(37) falling under the purview of paragraph 2(1)(u) of DPCO, 2013. The Authority approved the retail prices of 37 (Thirty-Seven) new drugs under paragraph 5 and 15 of DPCO, 2013 as given in **Table 1 below:**

Table No. 1: Retail price fixation of new drugs

Sl. No.	Name of the Formulation / Brand Name	Strength	Unit	Manufacturer & Marketing Company	Retail Price (Rs.)
(1)	(2)	(3)	(4)	(5)	(6)
1	Aceclofenac & Paracetamol Tablets	Each film coated tablet contains: Aceclofenac IP 100 mg Paracetamol IP 325 mg	1 Tablet	M/s Shiva Biogenetic Pharmaceuticals Pvt. Ltd./ M/s Softdeal Pharmaceutical Pvt. Ltd.	5.46
2	Albendazole & Ivermectin suspension	Each 5ml contains: Albendazole IP 200 mg Ivermectin IP 3 mg	1 ml	M/s Yacca Lifesciences Pvt. Ltd./ M/s Wockhardt Ltd.	1.39
3	Atorvastatin & Ezetimibe Tablets	Each Film Coated Tablet Contains: Atorvastatin Calcium IP Eq. to Atorvastatin 80mg Ezetimibe IP 10mg	1 Tablet	M/s Pure and Cure Healthcare Pvt. Ltd./ M/s Eris Lifesciences Ltd.	36.12
4	Bilastine & Montelukast Tablets	Each film coated Bi-layered tablet contains: Bilastine IP 40 mg Montelukast Sodium IP eq. to Montelukast 10mg	1 Tablet	M/s Akums Drugs & Pharmaceuticals Ltd./ M/s Cipla Ltd.	22.78
5	Bisoprolol fumarate & Telmisartan Tablets	Each film coated Bi-layered tablet contains: Bisoprolol fumarate IP 2.5 mg Telmisartan IP 40 mg	1 Tablet	M/s Mascot Health Series Pvt. Ltd./ M/s Primus Remedies Pvt. Ltd.	10.50
6	Bisoprolol fumarate & Telmisartan Tablets	Each film coated Bi-layered tablet contains: Bisoprolol fumarate IP 5 mg Telmisartan IP 40 mg	1 Tablet	M/s Mascot Health series Pvt. Ltd./ M/s Primus Remedies Pvt. Ltd.	12.00
7	Bisoprolol fumarate & Telmisartan Tablets	Each uncoated bilayered tablet contains: Bisoprolol fumarate IP 2.5 mg Telmisartan IP 40 mg	1 Tablet	M/s Windlas Biotech Pvt. Ltd./ M/s Dr. Reddys Laboratories Ltd.	10.00

Handa

Sl. No.	Name of the Formulation / Brand Name	Strength	Unit	Manufacturer & Marketing Company	Retail Price (Rs.)
(1)	(2)	(3)	(4)	(5)	(6)
8	Bisoprolol fumarate & Telmisartan Tablets	Each uncoated bilayered tablet contains: Bisoprolol fumarate IP 5 mg Telmisartan IP 40 mg	1 Tablet	M/s Windlas Biotech Ltd./ M/s Dr. Reddys Laboratories Ltd.	12.18
9	Calcium Aspartate, Calcium Orotate, Calcitriol, Minerals & vitamins tablets	Each Film Coated Tablet Contains: Calcium Aspartate 500 mg Calcium Orotate 500 mg Calcitriol IP 0.25 mcg Zinc (As Zinc Sulphate Monohydrate) IP 7.5 mg Magnesium Hydroxide IP 50 mg Hydroxocobalamin IP 100 mcg Folic Acid IP 1.5 mg	1 Tablet	M/s Troikaa Pharmaceuticals Ltd.	17.78
10	Calcium, Vitamin D3, Methyl cobalamin, L-Methyl folate Calcium & Pyridoxal-5-Phosphate Tablets	Each film coated tablet contains: Calcium Carbonate IP 1250 mg Eq. to Elemental Calcium 500 mg Vitamin D3 IP 2000 IU Methyl cobalamin IP 1500 mcg L-Methyl folate Calcium 1 mg Pyridoxal-5- Phosphate 20 mg	1 Tablet	M/s Pure & Cure Healthcare Pvt. Ltd. M/s Pharmed Ltd.	19.24
11	Cholecalciferol (Vitamin D3) Oral Solution	Each 5 ml contains: Cholecalciferol IP (In Nano Droplet form) 60000 IU	1 ml	M/s Ravenbhel Healthcare Pvt. Ltd./ M/s Troikaa Pharmaceuticals Ltd.	15.60
12	Dextromethorphan Hydrobromide, Phenylephrine Hydrochloride & Chlorpheniramine Maleate Syrup	Each 5 ml contains: Dextromethorphan Hydrobromide IP 15 mg Phenylephrine Hydrochloride IP 5mg Chlorpheniramine Maleate IP 2 mg	1 ml	M/s East African (I) Overseas / M/s SRK Puremed LLP	0.98
13	Levocetirizine Dihydrochlorid	Each 5ml contains: Levocetirizine	1 ml	M/s Tirupati Medicare Ltd./	1.67

Handa

Sl. No.	Name of the Formulation / Brand Name	Strength	Unit	Manufacturer & Marketing Company	Retail Price (Rs.)
(1)	(2)	(3)	(4)	(5)	(6)
	e & Montelukast Sodium Syrup	Dihydrochloride IP 2.5 mg Montelukast Sodium IP eq. to Montelukast 4 Mg		M/s German Remedies Pharmaceuticals Pvt. Ltd.	
14	Mefenamic acid & Paracetamol oral suspension	Each 5 ml contains: Mefenamic acid IP 50 mg Paracetamol IP 125 mg	1 ml	M/s East African (I) Overseas / M/s SRK Puremed LLP	0.77
15	Mefenamic acid & Paracetamol oral suspension	Each 5 ml contains: Mefenamic acid IP 100 mg Paracetamol IP 250 mg	1 ml	M/s East African (I) Overseas / M/s SRK Puremed LLP	0.92
16	Mefenamic acid & Paracetamol Tablets	Each uncoated tablet contains: Mefenamic Acid IP 500mg Paracetamol IP 325mg	1 Tablet	M/s East African (I) Overseas / M/s SRK Puremed LLP	3.91
17	Mefenamic Acid & Paracetamol Suspension	Each 5 ml contains: Mefenamic Acid IP 100 mg Paracetamol IP 250 mg	1 ml	M/s Skymap Pharmaceuticals Pvt. Ltd./ M/s Glensmith Labs Pvt. Ltd.	0.90
18	Mefenamic Acid & Paracetamol Suspension	Each 5 ml contains: Mefenamic Acid IP 100 mg Paracetamol IP 250 mg	1 ml	M/s Skymap Pharmaceuticals Pvt. Ltd./ M/s Jagsonpal Pharmaceuticals Ltd.	0.90
19	Meropenem & Sulbactam for Injection	Each vial contains: Sulbactam Sodium (Sterile) IP Equivalent to Sulbactam 500 mg Meropenem (Sterile) IP Equivalent to Anhydrous Meropenem 1000 mg Sodium Carbonate (As buffer) (Sterile) IP Equivalent to Sodium 90.2 mg	1 Vial	M/s Gufic Biosciences Ltd./ M/s Intas Pharmaceuticals Ltd.	1500
20	Myo-Inositol & Metformin Hydrochloride (SR) Tablets	Each Film Coated Bilayered Tablet Contains: Myo-Inositol IP 600 mg Metformin Hydrochloride IP 500 mg (As sustained release)	1 Tablet	M/s Akums Drugs & Pharmaceuticals Ltd. M/s Mankind Pharma Ltd.	23.59
21	Myo-Inositol & Metformin	Each Film Coated Bilayered Tablet Contains:	1 Tablet	M/s Akums Drugs & Pharmaceuticals	23.59

Handwritten signature

Sl. No.	Name of the Formulation / Brand Name	Strength	Unit	Manufacturer & Marketing Company	Retail Price (Rs.)
(1)	(2)	(3)	(4)	(5)	(6)
	Hydrochloride (SR) Tablets	Myo-Inositol IP 600 mg Metformin Hydrochloride IP 500 mg (As sustained release)		Ltd. M/s Emcure Pharmaceuticals Ltd.	
22	Myo-Inositol & Metformin Hydrochloride (SR) Tablets	Each Film Coated Bilayered Tablet Contains: Myo-Inositol IP 600 mg Metformin Hydrochloride IP 500 mg (As sustained release)	1 Tablet	M/s Akums Drugs & Pharmaceuticals Ltd. M/s Torrent Pharmaceuticals Ltd.	23.59
23	Moxifloxacin Hydrochloride & Ketorolac Tromethamine Ophthalmic solution	Composition: Moxifloxacin Hydrochloride IP Eq. to Moxifloxacin 0.5% w/v Ketorolac Tromethamine IP 0.5 % w/v Preservative: Benzalkonium Chloride solution IP 0.01% w/v	1 ml	M/s East African (I) Overseas / M/s Torrent Pharmaceuticals Ltd.	15.00
24	Multiple Electrolytes and 5% Dextrose Injection Type-I USP	Each 100 mL contains: Sodium Chloride IP 526 mg Sodium Gluconate USP 502 mg Sodium Acetate Trihydrate IP 368 mg Potassium Chloride IP 37 mg Magnesium Chloride Hexahydrate IP 30 mg Dextrose Monohydrate IP 5000 mg	1 pack of 500 mL	M/s Otsuka Pharmaceutical India Pvt. Ltd.	133.97
25	Paracetamol, Phenylephrine Hydrochloride & Chlorpheniramine Maleate Tablets	Each uncoated tablet contains: Paracetamol IP 500 mg Phenylephrine Hydrochloride IP 10 mg Chlorpheniramine Maleate IP 2 mg	1 Tablet	M/s East African (I) Overseas / M/s Intas Pharmaceuticals Ltd.	5.34
26	Paracetamol, Phenylephrine Hydrochloride & Chlorpheniramine Maleate Suspension	Each 5 ml contains: Paracetamol IP 250 mg Phenylephrine Hydrochloride IP 5 mg Chlorpheniramine Maleate IP 2 mg	1 ml	M/s Mascot Health Series Pvt. Ltd./ M/s Stedman Pharmaceuticals Pvt. Ltd.	1.36
27	Paracetamol, Phenylephrine	Each 5 ml contains: Paracetamol IP 125 mg	1 ml	M/s Mascot Health Series Pvt. Ltd./	1.31

Handa

Sl. No.	Name of the Formulation / Brand Name	Strength	Unit	Manufacturer & Marketing Company	Retail Price (Rs.)
(1)	(2)	(3)	(4)	(5)	(6)
	Hydrochloride & Chlorpheniramine Maleate Suspension	Phenylephrine Hydrochloride IP 5 mg Chlorpheniramine Maleate IP 2 mg		M/s Macleods Pharmaceuticals Ltd.	
28	Paracetamol, Phenylephrine Hydrochloride & Chlorpheniramine Maleate Suspension	Each 5 ml contains: Paracetamol IP 250 mg Phenylephrine Hydrochloride IP 5mg Chlorpheniramine Maleate IP 2mg	1 ml	M/s Mascot Health Series Pvt. Ltd./ M/s Macleods Pharmaceuticals Ltd.	1.36
29	Paroxetine (CR) & Clonazepam Capsules	Each hard gelatin capsule contains: Paroxetine Hydrochloride Hemihydrate IP Eq. to Paroxetine 12.5 mg (as enteric coated controlled release tablet) Clonazepam IP 0.25 mg (as uncoated Clonazepam Tablets IP)	1 Capsule	M/s Windlas Biotech Ltd./ M/s Ipca Laboratories Ltd.	15.53
30	Phenylephrine Hydrochloride & Chlorpheniramine Maleate Syrup	Each 5ml contains: Phenylephrine Hydrochloride IP 5 mg Chlorpheniramine Maleate IP 2 mg	1 ml	M/s East African (I) Overseas/ M/s SRK Puremed LLP	0.95
31	Povidone-Iodine & Metronidazole Ointment	Composition: Povidone-Iodine IP 5 % w/w (0.5 % w/w available Iodine) Metronidazole IP 1 % w/w	1 GM	M/s Stedman Pharmaceuticals Pvt. Ltd.	4.00
32	Tropicamide, Phenylephrine Hydrochloride & Lidocaine Hydrochloride Injection (Intracameral Injection)	Each ml contains: Tropicamide IP 0.2 mg Phenylephrine Hydrochloride IP 3.1 mg Lidocaine Hydrochloride IP 10 mg	1 ml AMPOULE	M/s Samarth Life Sciences Pvt. Ltd.	124.28
33	Vitamin D3 nano syrup	Each 5ml Contains: Cholecalciferol IP 60,000	1 ml	M/s Unicare India Ltd./	15.60

Handwritten signature 6

Sl. No.	Name of the Formulation / Brand Name	Strength	Unit	Manufacturer & Marketing Company	Retail Price (Rs.)
(1)	(2)	(3)	(4)	(5)	(6)
		IU (in Nano Droplet Form)		M/s Obsurge Biotech Ltd.	
34	Dapagliflozin and Telmisartan Tablets	Each film coated tablet contains: Dapagliflozin Propanediol USP eq. to Dapagliflozin 10 mg Telmisartan IP 40 mg	1 Tablet	M/s Exemed Pharmaceuticals/ M/s Glenmark Pharmaceuticals Ltd.	18.27
35	Glycopyrronium, Formoterol Fumarate, Budesonide Inhalation Suspension	Each Smartule contains: Glycopyrrolate IP Eq. to Glycopyrronium 25 mcg Formoterol Fumarate Dihydrate IP Eq. to Formoterol Fumarate 20 mcg Budesonide IP 500 mcg	1 ml	M/s Glenmark Pharmaceuticals Ltd.	49.00
36	Sitagliptin, Gliclazide (SR), Metformin Hydrochloride (SR) Tablets	Each film coated bilayered tablet contains: Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 100 mg Gliclazide IP 60 mg (As sustained release) Metformin Hydrochloride IP 500mg (As sustained release)	1 Tablet	M/s Eris Lifesciences Ltd.	22.91
37	Paracetamol, Chlorpheniramine Maleate Tablets	Each Uncoated Tablet Contains: Paracetamol IP 325 mg Chlorpheniramine Maleate IP 2 mg	1 Tablet	M/s Indoco Remedies Ltd.	6.80

5. Agenda item no. 5 - Minutes of 73rd meeting of Multidisciplinary Committee of Experts held on 25.11.2025.

5.1 Noted.

6. Agenda item no. 6 - Directions issued to M/s Serum Institute of India under Para-3 of DPCO, 2013 w.r.t. Tetanus Toxoide Vaccine (5ml & 0.5ml).

6.1 The Authority noted that direction under Para 3 of DPCO,2013 was issued to M/s Serum Institute of India Pvt. Ltd. on 22.01.2020 for continued production/sale in respect of Tetanus Toxoid Injection in two pack sizes i.e., (i) 0.5ml pack and (ii) 5 ml pack. The said directions were extended from time to time and is effective till 31.12.2025.

Handwritten signature

6.2 The Authority was briefed that the Immunization Division, MoH&FW vide email dated 18.12.2025 has confirmed that the Tetanus Toxoid vaccine was not procured by Central Medical Service Society (CMSS) during the last five years. Further, analysis of market data shows that there are other market players of the said subject formulations and the total MAT Values over the last 5 years is in the same range. Further, the market share of the M/s Serum Institute of India Pvt. Ltd. is 0.00% & 0.41% for Tetanus Toxoid 5ml pack and 0.5ml respectively based on Nov, 2025 market data.

6.3 In view of the above, the Authority decided not to further extend the period of said directions i.r.o. Tetanus Toxoid Injection in two pack sizes i.e., (i) 0.5ml pack and (ii) 5 ml pack manufactured by M/s Serum Institute of India Pvt. Ltd.

The Authority welcomed Shri Vijay Kumar, Adviser (Cost) O/o Chief Adviser (Cost) who has been nominated as a representative as O/o CAC, Department of Expenditure in place of Shri Manmohan Sachdeva, Additional Chief Adviser Cost (ACAC) who is due for retirement. The Authority acknowledged the contribution made by Sh. Manmohan Sachdeva as member of Authority.

The meeting ended with a vote of thanks to the Chair and all the participants in the meeting.


(Sai Ahladini Panda)
Member Secretary